Fresenius Medical Care Study Links GLP-1 Use to Lower Mortality in Dialysis Patients

• Fresenius Medical Care will present kidney care research at ASN Kidney Week in Denver, Oct. 21–25, 2026.
• A study of about 5,000 dialysis patients linked GLP-1 receptor agonist use to significantly lower mortality and fewer hospitalizations.
• U.S. clinical data showed high-volume hemodiafiltration using the 5008X CAREsystem achieved treatment targets comparable with European results.
• A U.S. study of integrated continuous kidney replacement therapy found citrate anticoagulation targets were maintained, with manageable electrolyte disturbances and no citrate toxicity.
• A separate study on GLP-1 treatment initiation and mortality in maintenance hemodialysis patients is scheduled for presentation Oct. 22, 10 a.m.–noon.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. FMC - Fresenius Medical Care AG published the original content used to generate this news brief on October 19, 2026, and is solely responsible for the information contained therein.